miR-133和EGFR在结肠癌组织中的表达及其临床意义

doi:10.3969/j.issn.1671-7171.2020.08.029

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the expression and clinical significance of miR-133 and epidermal growth factor receptor (EGFR) in colon cancer. 【Methods】 The expressions of miR-133 and EGFR were detected by real-time fluorescent quantitative PCR (RT-PCR); the correlation between miR-133 and EGFR was analyzed by Pearson; the effect of expression level on survival rate was analyzed by Kaplan Meier (K-M) survival curve.【Results】 The expression level of miR-133 in colon cancer tissues was significantly lower than that in normal tissues, while the expression of EGFR was significantly higher than that in normal tissues (P<0.05). There was a negative correlation between the expression of miR-133 and EGFR (r=-0.4941, P<0.01). The expression of miR-133 and EGFR were correlated with clinical stage, lymph node metastasis, TNM stage and pathological grade. The survival rate of patients with high expression of miR-133 was higher than that of the low expression group (P<0.05), while the survival rate of patients with high expression of EGFR was lower than that of the low expression group (P<0.05). 【Conclusion】 The expression of miR-133 and EGFR was increased in colon cancer, and they were negatively correlated with the prognosis of colon cancer. The combined detection of miR-133 and EGFR is expected to be an effective index and method for diagnosis and treatment of colon cancer.

Key words： Colonic Neoplasms/PA Receptor, Epidermal Growth Factor

Received: 21 July 2020

PACS:

R735.35

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Mei-Ling
	ZHANG Guang-Ying

Cite this article:

LI Mei-Ling,ZHANG Guang-Ying. Expression and Clinical Significance of miR-133 and EGFR in Colon Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1213-1215.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.08.029 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I8/1213

[1] Wang W. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities[J].Semin Cancer Biol,2019,55:37-52.
[2] Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis[J].Gastroenterology,2020,158(2):291-302.
[3] Lu TX, Rothenberg ME. MicroRNA[J].J Allergy Clin Immunol,2018,141(4):1202-1207.
[4] Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay[J].Nat Rev Genet,2010,11(9):597-610.
[5] Bushati N, Cohen SM. microRNA functions[J].Annu Rev Cell Dev Biol,2007,23:175-205.
[6] da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer[J].Annu Rev Pathol,2011,6:49-69.
[7] Tomasello C, Baldessari C, Napolitano M, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives[J].Crit Rev Oncol Hematol,2018,123:149-161.
[8] Hesari A, Azizian M, Darabi H, et al. Expression of circulating miR-17, miR-25, and miR-133 in breast cancer patients[J].J Cell Biochem,2018.[Online ahead of print]
[9] Zhang G, Wang J, Zheng R, et al. MiR-133 Targets YES1 and inhibits the growth of triple-negative breast cancer cells[J].Technol Cancer Res Treat,2020,19:1533033820927011.
[10] Cheng Z, Liu F, Wang G, et al. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer[J].Cell Signal,2014,26(12):2667-2673.
[11] Liu Y, Han L, Bai Y, Du W, Yang B. Down-regulation of MicroRNA-133 predicts poor overall survival and regulates the growth and invasive abilities in glioma[J].Artif Cells Nanomed Biotechnol,2018,46(1):206-210.
[12] Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer[J].Scand J Urol,2013,47(5):423-432.
[13] Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades[J].Cold Spring Harb Perspect Biol,2014,6(3):a008912.
[14] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer[J].Mol Oncol,2018,12(1):3-20.
[15] Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer[J].J Thorac Oncol,2017,12(4):612-623.
[16] Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era[J].Cancer Metastasis Rev,2017,36(3):463-473.
[17] Koustas E, Karamouzis MV, Mihailidou C, et al. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer[J].Cancer Lett,2017,396:94-102.
[18] Xu F, Li F, Zhang W, et al. Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression[J].Tumour Biol,2015,36(12):9553-9558.
[19] Liu S, Chen J, Zhang T, et al. MicroRNA-133 inhibits the growth and metastasis of the human lung cancer cells by targeting epidermal growth factor receptor[J].J BUON,2019,24(3):929-935.
[20] Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer[J].Scand J Urol,2013,47(5):423-432.